Travere Therapeutics (NASDAQ:TVTX) Receives Overweight Rating from Cantor Fitzgerald
Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. Other equities research analysts have also recently issued reports about the company. Evercore ISI increased their price target on Travere Therapeutics from $33.00 to $45.00 and gave the company […]
Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. Other equities research analysts have also recently issued reports about the company. Evercore ISI increased their price target on Travere Therapeutics from $33.00 to $45.00 and gave the company […]
